why choose us

First received: February 23, 2023

Clinical Trial: A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Non-alcoholic Steatohepatitis

Study Type: INTERVENTIONAL


Official Title: Investigation of Pharmacokinetics Following Administration of NNC0194-0499 and Semaglutide as Co-formulation Versus Separate Injections in Healthy Participants

Brief Summary: Novo Nordisk is developing a combination of 2 medicines (NNC0194-0499 and semaglutide) for the treatment of nonalcoholic steatohepatitis (NASH).NASH is a serious disease where fat, inflammation and scar tissue builds up in the liver.NNC0194-0499 is a new medicine which works in the liver.Semaglutide is a well-known medicine, which is already used to treat type 2 diabetes and obesity.The study is being done to see how 2 medicines (NNC0194-0499 and semaglutide) are absorbed, transported, and eliminated from the body…

Read more